Gilead Sciences Inc
Change company Symbol lookup
Select an option...
GILD Gilead Sciences Inc
SFDMY Shanghai Fudan Microelectronics Group Co Ltd
PTNR Partner Communications Company Ltd
CHPT ChargePoint Holdings Inc
BASMX iShares Total U.S. Stock Market Index Fund Investor A Shares
FLNT Fluent Inc
CCXI ChemoCentryx Inc
NVTA Invitae Corp
CLNE Clean Energy Fuels Corp
IMBBY Imperial Brands PLC
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases includes Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. It sells and distributes its products in the United States through the wholesale channel. It operates in more than 35 countries worldwide.

Closing Price
$61.60
Day's Change
0.51 (0.83%)
Bid
--
Ask
--
B/A Size
--
Day's High
61.71
Day's Low
60.81
Volume
(Below Average)
Volume:
5,857,705

10-day average volume:
6,873,514
5,857,705

Display:

Providers:

UpdateCancel
6 providers
August 04, 2022
Gilead Sciences to Acquire MiroBio

--- MiroBio's Scientific Approach to Restoring Immune Balance for the Treatment of Autoimmune Diseases Complements Gilead's Inflammation Research and Development Strategy - Gilead Sciences, Inc. (Nasdaq: GILD) and MiroBio, a privately-held...(BusinessWire)

August 02, 2022
Gilead Sciences Announces Second Quarter 2022 Financial Results

--Oncology Sales Increased 71% Year-Over-Year to $527 million Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter of 2022. "This was a very strong quarter for Gilead, with solid commercial and...(BusinessWire)

July 28, 2022
Biktarvy(R) Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV Coinfection

--- No Cases of Treatment Failure Due to Resistance to Biktarvy was Detected in a Pooled Analysis of Five-Year Data from Two Phase 3 Studies - Gilead Sciences, Inc. (Nasdaq: GILD) today announced results reinforcing Biktarvy(R) (bictegravir 50...(BusinessWire)

July 27, 2022
AlloVir Announces $126.6 Million Registered Direct Offering

AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage allogeneic T-cell immunotherapy company, today announced that it has entered into a securities purchase agreement with a group of institutional and strategic investors to sell 27,458,095 shares of...(BusinessWire)

July 22, 2022
Kite's CAR T-cell Therapy Tecartus(R) Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)

--- If Approved, it will Address a Significant Unmet Need for a Patient Population with Limited Treatment Options - Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Medicines Agency (EMA) Committee for Medicinal Products for...(BusinessWire)

CHMP Adopts Positive Opinion Recommending Veklury(R) (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Commission (EC) adopted a positive opinion on the fulfillment of the last specific obligation and recommended the...(BusinessWire)

July 21, 2022
Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic

--- Key Initiatives Highlight Role of Catalytic Collaboration to Help End the Epidemic for Everyone, Everywhere - Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming contributions to the 24th International AIDS Conference (AIDS 2022)...(BusinessWire)

July 20, 2022
Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an $85 million contribution to the Gilead Foundation to further the company's vision of creating a healthier world for all people. This donation builds on the endowment Gilead announced last year...(BusinessWire)

July 19, 2022
Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury(R) (Remdesivir)

Gilead Sciences and the European Commission today signed a new joint procurement agreement (JPA) that will ensure continued rapid and equitable access to Veklury(R) (remdesivir) for participating Member States across the European Union (EU) and...(BusinessWire)

July 12, 2022
Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2022 financial results will be released on Tuesday, August 2, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to...(BusinessWire)

Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Deborah Telman will join the company as Executive Vice President, Corporate Affairs and General Counsel, and will become a member of the company's senior leadership team, reporting to...(BusinessWire)

June 28, 2022
Kite's CAR T-cell Therapy Yescarta(R) Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma

--- Kite's Third Approved Cell Therapy Indication in Europe - Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Commission (EC) has approved its CAR T-cell therapy Yescarta(R) (axicabtagene ciloleucel) for the treatment of...(BusinessWire)

June 27, 2022
Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor

--- If Approved, Lenacapavir Would be the First and the Only HIV-1 Treatment Option Administered Twice-Yearly - Gilead Sciences, Inc. (Nasdaq: GILD) today announced the resubmission of the New Drug Application (NDA) to the U.S. Food and Drug...(BusinessWire)

Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases

Gilead Sciences today announced that the company has signed onto the Kigali Declaration on neglected tropical diseases (NTDs) which succeeds the London Declaration on NTDs. It was launched on the margins of the Commonwealth Heads of Government...(BusinessWire)

June 24, 2022
Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV

--- If Authorized, Lenacapavir Could Offer a New, Every Six-Month Treatment Option for People with Limited Treatment Choices - Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...(BusinessWire)

June 23, 2022
Treatment With Hepcludex(R) (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks

Gilead Sciences, Inc. (Nasdaq: GILD) today announced Week 48 results from the Pivotal Phase 3 clinical trial evaluating the first-in-class entry inhibitor Hepcludex(R) (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV) infection...(BusinessWire)

June 21, 2022
Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress(TM) 2022

--- Oral Presentations of Latest Phase 3 Hepcludex(R) (bulevirtide) Efficacy and Safety and Patient-Reported Outcomes Data Reinforce the Clinical Importance of the First-in-Class Treatment for HDV - Gilead Sciences, Inc. (Nasdaq:GILD) today...(BusinessWire)

June 06, 2022
Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC

Gilead Sciences, Inc. (Nasdaq: GILD) today presented final data from the Phase 3 ASCENT study of Trodelvy(R) (sacituzumab govitecan-hziy) in patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC) who received two or...(BusinessWire)

June 04, 2022
Tecartus(R) Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up of Two Pivotal Studies Including Longest Ever Follow-Up of a CAR T-cell Therapy in Mantle Cell Lymphoma

-- In Two-Year Follow-up in Adults with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Tecartus Induced High Rates of Durable Response (CR+CRi 73.1%) and a Median Overall Survival of 25.4 Months -- (BusinessWire)

Sub-analyses of Landmark ZUMA-7 Trial Reinforce Yescarta(R) CAR T-cell Therapy Superiority Over Standard of Care (SOC) as Initial Treatment for Patients With Relapsed or Refractory Large B-cell Lymphoma (LBCL)

-- Separate Exploratory Analysis Found Yescarta Benefit vs SOC Was Consistent Across Subgroups, Including in Patients with High Tumor Burden and Elevated Lactate Dehydrogenase (LDH) -- Kite, a Gilead Company (Nasdaq: GILD), today announced findings...(BusinessWire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.